tbuckley/cabot-search huggingface dataset:
Outcome of 116 cases of pleuropulmonary blastoma type I and type Ir (regressed): A report from the International PPB Registry (IPPBR).
Authors: Yoav H. Messinger, Gretchen M Williams, John R. Priest, Anne Harris, Leslie Ann Doros, Kris Ann Pinekenstein Schultz, Louis P Dehner, D Ashley Hill
Journal: Journal of Clinical Oncology (2012)

9522 Background: Pleuropulmonary blastoma (PPB) is a rare dysembryonic lung neoplasm of early childhood with progression from a purely cystic Type I (T-I) lesion to cystic solid and solid high grade sarcoma (Type II and Type III). A regressed form of PPB (T-Ir) has been recognized pathologically. The outcome of both T-I and T-Ir has been only partially described. Methods: Retrospective analysis of 345 IPPBR cases showed 116 T-I or T-Ir. In all cases the PPB diagnosis was made on surgically removed cysts. The treating physician decided whether to use chemotherapy after surgery. Results: The pathologic diagnosis of the 91 PPB T-I and 25 T-Ir is now confirmed by central review (LPD and DAH). Patients with T-I were younger than T-Ir (median: 8 months vs. 48 months).Diagnosis after age 6 years included only one T-I compared to 10 T-Ir patients. Therapy is not known for 28 T-I and 2 T-Ir. Surgery was followed by chemotherapy in 31 T-I and 2 T-Ir. Six (5%) recurred with the same type, all were alive at last follow-up: 5 (5.5%) T-I, 1 (4%) T-Ir. Progression to high-grade Type II or III occurred in 9/91 (10%) T-I and 2/25 (8%) T-Ir. The addition of chemotherapy did not significantly reduce progressions (Fisher’s exact test). All of the tumor progressions were seen by 75 months of age; this finding is similar to broader IPPBR data: &gt; 95% of patients are diagnosed with Type II/III by 72 months of age. Of the 9 patients with T-I who progressed, 5 ultimately died, whereas the 2 T-Ir who progressed were alive. At last follow-up 111/116 (95.6%) were alive. Conclusions: A cyst in an older individual most likely will be Type Ir. Type I and Type Ir are clinically similar with a small risk of progression to the advanced Type II/III up to 6 years of age. Outcome for those whose cystic PPBs progressed is poor. The role of chemotherapy remains uncertain for the prevention of progression in the pure cystic PPB Type I or Ir. [Table: see text]
DIRECT HOME DISCHARGE AND LIKELIHOOD OF 30-DAY HOSPITAL READMISSION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): FINDINGS FROM THE STS/ACC TVT REGISTRY
Authors: John A. Dodson, Mathew Williams, Sreekanth Vemulapalli, Pratik Manandhar, David Cohen, Caroline Blaum, Hua Zhong, John Rumsfeld, Judith Hochman
Journal: Journal of the American College of Cardiology (2017)
The Long-HER study: Clinical and molecular analysis of advanced HER2+ breast cancer treated with trastuzumab and associated to long-term survival.
Authors: Enrique Espinosa, Angelo Gámez-Pozo, Ramon Maria Perez Carrion, Luis Manso, Carmen Crespo, Cesar Mendiola, Isabel Alvarez, Mireia Margeli, Juan L. Bayo, Xavier Gonzalez, Ana Santaballa, Eva Ciruelos, Miguel Angel Cabrera, Antonio Anton, Gustavo Catalan, José Valero Álvarez Gallego, Jose Miramon, Rocio Lopez Vacas, Pilar Zamora
Journal: Journal of Clinical Oncology (2013)

608 Background: Some patients with advanced HER2+ breast cancer survive in the long-term after receiving trastuzumab-based therapy. Long-HER study was an observational, multicenter study that compared long-term survivors and a control group from the clinical and molecular point of view. Methods: Patients with metastatic HER2+ breast cancer that had been treated with trastuzumab-based therapy and had an objective response or stable disease for at least 3 years were included. A control group having a progression in the first year of therapy was selected for comparison (similar first-line therapy). A microarray platform was used to assess whole genome expression analysis in paraffin-embedded samples. Differential expression, ontology and analysis of metabolic pathways were performed. Results: 103 patients were registered, 71 of who had a long-term complete remission. Only 5 of these patients had received trastuzumab in the adjuvant setting: this was the only clinical factor associated to long-term survival. The molecular study included 35 Long-HER and 18 control samples. Gene expression ontology revealed alterations in HIF, apoptosis, and EGF, PI3K and p53 pathways. The PI3K pathway was mostly related with a poor response to therapy. Conclusions: trastuzumab-based therapy achieves long-term survival in a selected group of women with advanced HER2-positive breast cancer. Whole genome analysis comparing such a group with a control group found some alterations that may predict early progression to trastuzumab.
Demographics of uterine serous cancer (USC) patients: A single institutional experience.
Authors: Maria de Leon, Lingeng Lu, Pei Hui, Alessandro Santin, Thomas J. Rutherford, Dan Arin-Silasi, Masoud Azodi, Elena Ratner, Peter E. Schwartz
Journal: Journal of Clinical Oncology (2012)

e15581 Background: The common uterine cancer (UC) occurs in obese, diabetic (DM), hypertensive (HTN), postmenopausal women and are estrogen dependent. Small institutional series suggest USC occurs in older, thin women and is not associated with estrogen dependency. The objective of this study is to report demographic features of USC patients (pts) in a large single-institution experience and compared them with SEER data for UC (National Cancer Institute, SEER 2004-2008, uterine cancer. http://seer.cancer.gov/statistics/ ). Methods: Institutional records were reviewed from 1987 to 2009. Pts age, menopause status, race, disease stage, histology, past medical history (PMH) and additional demographics were collected. Results: 334 USC (pts) were identified. Their average age at diagnosis was 69.1 years (range 37-92). 282 (88.1%) were Caucasian and 32 (10%) were African Americans. The FIGO stage was IA 121 (36.2%), IB 36 (10.8%), II 27 (8.1%), IIIA 39 (11.7%), IIIB 2 (0.6%), IIIC1 32 (9.6%), IIIC2 9 (2.7%), IVA 28 (8.4%) and IVB 40 (12%). PMH revealed 177 of 221 (80%) had HTN and 69 of 221 (32%) had DM. 132 of 292 (45.3%) were obese; 95 (32.5%) had BMI between 30-39,31 (10.6%) had BMI between 40-49 and 6 (2.1%) had BMI &gt;50. 89 of 315 (28.2%) smoked cigarettes, 48 of 250 (19.2%) used oral contraceptives for an average of 4 years (range 1-15) and 42/299 (14%) used HRT for an average of 4 years (range 1-20). 35 (17.3%) had a prior history of breast cancer, 5 (2.5%) colon cancer and 13 (6.4%) had other forms of cancer. Compared to published SEER data 1 for all UC, more USC pts were diagnosed with advanced stage disease (II-IVB) 53% vs. 28%. USC patients were older at diagnosis (mean age of 69 vs. 61 years). Conclusions: Like UC, USC often presents in obese (45.3%), hypertensive (80%) diabetic (33%) women who have a prior history of breast cancer (17%). However, USC typically is found in older pts and at a more advanced stage.
CHADS2 SCORE PREDICTS OUTCOMES OF RADIOFREQUENCY CATHETER ABLATION IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Madhu Reddy, Valay Parikh, M. Rizwan Afzal, Darbhamulla Nagarajan, Luigi Di Biase, Ajay Vallakati, John Burkhardt, Linda Umbarger, Sudharani Bommana, Prasant Mohanty, Rodney Horton, Donita Atkins, James Vacek, Buddhadeb Dawn, Andrea Natale, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
Impact of tapered-cuff tracheal tube on microaspiration of gastric contents in intubated critically ill patients: a multicenter cluster-randomized cross-over controlled trial
Authors: Emmanuelle Jaillette, Christophe Girault, Guillaume Brunin, Farid Zerimech, Hélène Behal, Arnaud Chiche, Céline Broucqsault-Dedrie, Cyril Fayolle, Franck Minacori, Isabelle Alves, Stéphanie Barrailler, Julien Labreuche, Laurent Robriquet, Fabienne Tamion, Emmanuel Delaporte, Damien Thellier, Claire Delcourte, Alain Duhamel, Saad Nseir
Journal: Intensive Care Medicine (2017)
DISCRIMINANT VALUE OF THE DAPT SCORE TO PREDICT LONG-TERM ISCHEMIC AND BLEEDING EVENTS IN THE REAL WORLD POPULATION OF STENTED PATIENTS IN THE FAST-MI 2005 COHORT
Authors: Tabassome Simon, Etienne Puymirat, Francois Schiele, Pierre Coste, Denis Angoulvant, Khalife Khalife, Guillaume Cayla, Pascal Motreff, Ferrieres Jean, Nicolas Danchin
Journal: Journal of the American College of Cardiology (2017)
Circulating Interleukin 6 in Parkinson Disease—Reply
Authors: Xiao-Yan Qin, Yong Cheng
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
IMPLICATIONS OF THE FDA APPROVAL OF PCSK9 INHIBITORS FOR CONTEMPORARY CARDIOVASCULAR PRACTICE: FINDINGS FROM THE NCDR ® RESEARCH TO PRACTICE (R2P) PROJECT
Authors: Paul Hess, Kevin Kennedy, Michael Cowherd, Salim Virani, Frederick Masoudi, Ann Marie Navar, Robert Yeh, Thomas Maddox
Journal: Journal of the American College of Cardiology (2017)
Abstract P082: Cardiac Calcium Handling and Protein Phosphatase 2A Activity Are Differentially Regulated by JNK1 and JNK2 MAP Kinases
Authors: Honey B Golden, Linley E Watson, Donald M Foster, David E Dostal
Journal: Circulation Research (2011)

We previously identified the JNK-B56α-PP2A signaling axis as a major target in anthrax lethal toxin (LT)-induced cardiac dysfunction. Thus, we further tested whether LT-mediated loss in cardiac function is a consequence of dysregulated calcium handling resulting from JNK inactivation. To biochemically recapitulate the signaling effects of LT, we infected NRVM with HA-B56α adenovirus and determined PP2A activity as well as Ca 2+ i measurements. Over-expression of HA-B56α in NRVM did not induce a significant increase in cellular PP2A activity, however, it did induce a significant increase (p&lt;0.01) in Ca 2+ i compared to virus control. Furthermore, PLB, PP2Ac and Akt protein co-immunoprecipitated with HA-B56α, and immunostaining revealed colocalization of B56α with PLB at the SR. Since B56α over-expression alone was not sufficient to induce PP2A activity or PP2A-mediated Ca 2+ i dysregulation, we hypothesized that JNK may serve as a functional regulator of Ca 2+ i handling through PP2A activation as well as B56α protein levels. Adenoviral-mediated over-expression of MEK7 in NRVM resulted in a significant reduction in LT-mediated Ca 2+ i dysregulation compared to virus control (p&lt;0.01). To further determine whether the protection of MEK7 is mediated by JNK1 or JNK2, gain-of-function/loss-of-function experiments were performed utilizing adenoviral constructs for CA-MEK7, DN-JNK1 and DN-JNK2. Results confirmed that the protective effect of active MEK7 over-expression on Ca 2+ i was significantly lost with knock-down of JNK1 compared to JNK2 (p&lt;0.05), suggesting that JNK1 plays a more substantial role in regulating PP2A activity than JNK2. Furthermore, the selective knock-down of JNK1 also increased Ca 2+ i levels (p&lt;0.001) compared to MEK7 during LT treatment, which reveals the importance of JNK1 in PP2A-mediated Ca 2+ i dysregulation. Interestingly, immunoblotting of PLB did not reveal a JNK-dependent difference in PLB phosphorylation at Ser 16 , however, loss of JNK2 almost completely inhibited p-PLB-Thr 17 . Thus, our results suggest that JNK1 and JNK2 may differentially regulate Ca 2+ i through PP2A activation and PLB-Thr 17 phosphorylation, respectively.
ECHOCARDIOGRAPHIC PREDICTORS FOR IN-HOSPITAL AND 1-YEAR OUTCOMES IN LEFT-SIDED INFECTIVE ENDOCARDITIS: AN ANALYSIS FROM THE INTERNATIONAL COLLABORATION ON ENDOCARDITIS-PROSPECTIVE ECHO COHORT STUDY
Authors: Trine K. Lauridsen, Lawrence Park, Christine Selton-Suty, Gail Peterson, Stuart Dickerman, Enrico Cecchi, Gilbert Habib, Magnus Johansson, Stamatios Lerakis, Syahidah Tamin, Franck Thuny, Javier Bermejo, Carlos Pare, Niels Eske Bruun, Vivian Chu, Vance Fowler, Andrew Wang, Anna Lisa Crowley
Journal: Journal of the American College of Cardiology (2017)
TRANSCATHETER MITRAL VALVE REPAIR(MITRA CLIP) IN UNITED STATES: LENGTH OF STAY AND COST OF HOSPITALIZATIONS FROM THE NATIONWIDE READMISSION DATABASE.
Authors: Sidakpal Panaich, Shilpkumar Arora, Elad Maor, John Rapheal, Nilay Patel, Apurva Badheka, Abhishek Deshmukh, Mackram Eleid, Harshil Shah, Byomesh Tripathi, Ala Asasad, Kosha Thakore, Charanjit Rihal
Journal: Journal of the American College of Cardiology (2017)
Chemoimmunotherapy for Patients with Chronic Lymphocytic Leukemia: MD Anderson Experience Beyond FCR300
Authors: Dai Chihara, Philip A Thompson, Hagop M. Kantarjian, Susan M. O'Brien, Alessandra Ferrajoli, Nitin Jain, Jan A Burger, Zeev Estrov, Stefan Faderl, William G. Wierda, Michael J. Keating
Journal: Blood (2016)
A RETROSPECTIVE STUDY OF THE EFFECT OF COLCHICINE ADMINISTRATION TIMING ON THE INCIDENCE OF POST-OPERATIVE ATRIAL FIBRILLATION AFTER A NON TRANSPLANT CARDIAC SURGERY
Authors: Alex H. Velasquez, Fiorella Llanos-Chea, Ignacio De Ciccio, S. Humayun Naqvi, Victor Liu, Anne Dougherty
Journal: Journal of the American College of Cardiology (2017)
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
Authors: Suzanne Fields Jones, Carla Kurkjian, Manish R. Patel, Jeffrey R. Infante, Howard A. Burris, F Anthony Greco, Michael Brian Hemphill, Adil I. Mohyuddin, Dana Shelton Thompson, Patrick Murphy, Eric Raefsky, Johanna C. Bendell
Journal: Journal of Clinical Oncology (2013)

2544 Background: C-Met protein is a receptor tyrosine kinase which is overexpressed or mutated in a variety of tumor types, causing cell proliferation, metastasis, and angiogenesis. Tivantinib is an orally bioavailable small molecule which binds to the c-Met protein. This phase I study was designed to determine the maximum tolerated dose (MTD) of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors. Methods: Patients with advanced solid tumors for which FOLFOX (5-FU IV 400 mg/m 2 day 1; 5-FU CIV 2400 mg/m 2 day 1; Leucovorin IV 400 mg/m 2 day 1; Oxaliplatin IV 85 mg/m 2 day 1) would be appropriate chemotherapy received escalating doses of tivantinib BID (days 1-14) in a standard 3 + 3 design. Dose-limiting toxicities (DLTs), non-dose-limiting toxicities (NDLTs), safety, and preliminary efficacy were evaluated. Results: Fourteen patients (50% colorectal) were treated across 3 dose levels: 120 mg (n=3); 240 mg (n=5); 360 mg (n=6). No DLTs were observed until the 3 rd dose level (treatment delay ≥3 days, secondary to grade 3 neutropenia). Common related adverse events (% grade 1/2; % grade 3/4) included: diarrhea (36%; 0%), neutropenia (0%; 29%), nausea (14%; 14%), vomiting (14%; 14%), dehydration (14%; 7%), and thrombocytopenia (14%; 0%). To date, 7 patients have been evaluated for response including 4 (57%) with stable disease evident at the 8-week evaluation (CRC, 2 patients; unknown primary favoring CRC, 1 patient; esophageal, 1 patient) and 3 (21%) with disease progression. The 4 patients with stable disease are continuing on treatment; three (CRC and unknown primary) had received prior FOLFOX. Conclusions: The addition of tivantinib to standard therapy FOLFOX appears tolerated up to its recommended phase II monotherapy dose of 360 mg. Preliminary efficacy is encouraging, and a phase II study is proceeding with this regimen for the first line treatment of advanced gastroesophageal patients. Clinical trial information: NCT01611857.
Surveillance and follow up of pediatric cancer from a developing country.
Authors: Argha Nandy, Soma Mukhopadhyay, Debdatta Maity, Gouri Shankar Bhattacharyya, Ashis Mukhopadhyay
Journal: Journal of Clinical Oncology (2013)

10069 Background: Childhood cancers, a leading cause of childhood deaths, affect more than 200,000 children worldwide, of which &gt;80% are from developing nations. This demands for proper measurement of the incidence of various childhood cancers which led to a novel study in assessing the burden of childhood cancers in eastern India through analysis of hospital-based cancer registry data from our institute in between January 2001- December 2011. Methods: 3,200pediatriccancer patients between 0-15 yearsdiagnosed by means of histological and cytological examinations were included in this study. Based on histopathological classification, cancer cases were distributed into 3 different age groups. Their respective family functioning, mental health, self-esteem and social competence were examined. Details of disease, tobacco usage along with socio demographic data were collected through standard questionnaires. Comparative measures of disease incidence were also calculated. For measuring the tolerance, different drugs were administered to patients. Results: The incidence of different malignancies was recorded which were Leukemia (34.9%), Lymphoma (24.1%), Hodgkin’s disease (18.1%), NHL (6.0%), Ewing’s sarcoma (4.9%), Rhabdomyosarcoma (3.6%), Neuroblastoma (2.0%), Brain tumour (9.9%), Wilm’s tumour (6.0%), Lymphoid Leukemia (26.9%), Myeloid Leukemia (7.9%), Germ cell tumour (4.2%), Osteosarcoma (4.0%), Retinoblastoma (2.0%) and Soft tissue sarcoma (2.3%). The disease free survival (DFS) for ALL was 76%, NHL (84%), Soft tissue sarcoma (78%), CML (98%), AML (48%) and germ cell tumour (95%). Finally, 53.33% patients were subjected to post-therapy assessment, of which 98% showed no after effect of therapy on growth chart, heart and endocrine function. The toxicity of grade III and IV chemotherapy ranges from 10-20%. Conclusions: Based on our study, the most happening cancer was Leukemia (34.9%) followed by Lymphoma (24.1%) and soft tissue sarcoma (18%). The overall disease free survival for pediatric patients was 72% with acceptable toxicity. Our results are comparable with the studies of other developed countries.
Response assessment using dynamic MR imaging in non-metastatic osteosarcoma
Authors: W. E. Reddick, F. A. Hoffer, C. A. Billups, J. J. Jenkins, J. Wu, N. C. Daw
Journal: Journal of Clinical Oncology (2007)

10018 Background: Conventional static imaging methods are of limited utility in assessing osteosarcoma (OS) response to neoadjuvant chemotherapy primarily due to the lack of significant change in tumor size. Methods: We prospectively evaluated the utility of dynamic contrast-enhanced MR imaging (DEMRI) in assessing tumor response as part of a phase II trial of multiagent chemotherapy for treatment of OS from 1999 to 2006. Forty-two subjects (median age, 13.5 years) with non-metastatic OS of the extremity (27 femur, 10 tibia, 3 humerus, 1 fibula, and 1 ulna) underwent one or more DEMRI examinations and had histological assessment of tumor response. DEMRI was performed at baseline (before course 1 of chemotherapy [week 0]), at week 9 (after 3 courses of chemotherapy), and at week 12 (after 4 courses of chemotherapy before definitive surgery). Quantitative DEMRI measures reflecting rate and intensity of enhancement (dynamic vector magnitude [DVM]) and regional contrast transfer between the plasma and extracellular/extravascular spaces (k ep ) were analyzed in relation to histological response. Nonparametric Wilcoxon signed-rank test was used to compare DEMRI parameters during preoperative chemotherapy with baseline. Logistic regression was used to examine the association between DEMRI parameters and histological response at each time point. Results: Both DEMRI parameters at week 9 and at week 12 of preoperative chemotherapy were significantly decreased from baseline (p&lt;0.001). Patients with lower DVM or lower k ep at week 9 or at week 12 ( Table ) were significantly more likely to have good histological response (&gt;90% tumor necrosis). Conclusions: DEMRI is a non-invasive method that can be used to assess tumor response to neoadjuvant chemotherapy in OS. A slower rate of contrast accumulation in the extracellular/extravascular space corresponds to increased tumor necrosis. [Table: see text] No significant financial relationships to disclose.
THE FEASIBILITY AND SAFETY OF SAME DAY DISCHARGE FOR ALL COMERS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS
Authors: Ali Hama Amin, Sami Aljohani, Peter Farjo, Kinjan Patel, Mohammad Akram Kawsara, Fahad Alqahtani, Chalak Berzingi, Anthony Roda-Renzelli, Jason Moreland, Wissam Gharib, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative
Authors: Emilia L. Lim, Diane L. Trinh, Rhonda E. Ries, Yussanne Ma, James Topham, Maya D. Hughes, Erin Pleasance, Andrew J. Mungall, Richard Moore, Yongjun Zhao, Daniela S. Gerhard, Vivian Oehler, E. Anders Kolb, Alan S. Gamis, Malcolm A. Smith, Todd A. Alonzo, Robert J. Arceci, Soheil Meshinchi, Marco A. Marra
Journal: Blood (2015)